

ONCOSEC MEDICAL Inc  
Form 8-K/A  
July 07, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A**

Amendment No. 1

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **February 3, 2011**

**ONCOSEC MEDICAL INCORPORATED**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-54318**  
(Commission  
File Number)

**98-0573252**  
(I.R.S. Employer  
Identification No.)

**4690 Executive Drive, Suite 250**  
**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

Registrant's telephone number, including area code: **(855) 662-6732**

**Not Applicable**

## Edgar Filing: ONCOSEC MEDICAL Inc - Form 8-K/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Explanatory Note**

This Current Report on Form 8-K/A ( Form 8-K/A ) is filed as an amendment to the Current Report on Form 8-K filed by OncoSec Medical Incorporated (the Company ) with the Securities and Exchange Commission on February 4, 2011 (the Original Form 8-K ). The sole purpose of filing this Form 8-K/A is to provide information called for in Item 5.02(d)(3) that had not been determined at the time of the filing of the Original Form 8-K.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On June 30, 2011, the Board of Directors (the Board ) of the Company established the following committees of the Board: Audit Committee; Compensation Committee; Nominating and Corporate Governance Committee; Financing Committee; and Clinical and Regulatory Affairs Committee. In connection with the establishment of such committees, director Dr. James DeMesa was appointed to certain of such committees of the Board, as follows: Audit Committee; Compensation Committee; and Nominating and Corporate Governance Committee (Chairman).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ONCOSEC MEDICAL INCORPORATED**

Dated: July 7, 2011

By:

*/s/ Punit Dhillon*

Name: Punit Dhillon

Title: President & Chief Executive Officer